Estradiol Valerate CAS 979-32-8

Estradiol valerate More Info

Estradiol valerate, identified by the Chemical Abstracts Service Registry Number 979-32-8, is a synthetic ester and prodrug of the primary human estrogen, 17β-estradiol. As a molecule, it consists of the natural estradiol hormone esterified with valeric acid at the 17-beta position, a modification that dramatically enhances its lipophilicity and oral bioavailability compared to estradiol alone. Its molecular formula is C₂₃H₃₂O₃, with a molecular weight of approximately 356.50 grams per mole, and its systematic IUPAC name is 17-pentanoyl-estra-1,3,5(10)-triene-3,17β-diol. This structural alteration allows the drug to survive first-pass metabolism in the liver after oral ingestion, after which the ester side chain is cleaved to release active, bioidentical estradiol into the systemic circulation. In its pure form, it is a white or almost white crystalline powder that is practically insoluble in water but soluble in organic solvents such as  acetone, reflecting its hydrophobic character.

The pharmacological mechanism of estradiol valerate is intrinsically linked to its function as a hormone replacement agent. Following absorption and cleavage of the valerate ester, the liberated estradiol acts as a potent agonist of estrogen receptors, specifically the ERα and ERβ subtypes, which are distributed widely throughout the body in tissues such as the uterus, breasts, hypothalamus, pituitary gland, bone, liver, and skin. By binding to these nuclear receptors, the estradiol-receptor complex translocates to the cell nucleus, where it regulates the transcription of numerous genes involved in cellular growth, differentiation, and function. This genomic action underpins the development and maintenance of female reproductive tissues and secondary sexual characteristics, as well as the regulation of gonadotropin secretion, bone density preservation, and vascular health. In clinical contexts, exogenous administration aims to restore physiological levels of estrogen when endogenous production is deficient or to create a specific hormonal environment for therapeutic purposes.

The clinical applications of estradiol valerate are diverse and well-established across several medical fields. It is most commonly indicated for hormone replacement therapy in postmenopausal women to alleviate moderate to severe vasomotor symptoms such as hot flushes and night sweats, as well as to treat vulvovaginal atrophy and prevent osteoporosis. In women with primary ovarian failure, hypogonadism, or those who have undergone surgical castration, it serves to correct estrogen deficiency states and support normal physiological function. In reproductive medicine, particularly in assisted reproductive technology cycles, estradiol valerate is frequently used to promote endometrial proliferation and thickening, thereby improving the uterine lining for embryo implantation and supporting early pregnancy. Additionally, in oncological settings, high-dose estradiol valerate administered parenterally has been utilized for palliative treatment in patients with advanced androgen-dependent carcinoma of the prostate. It is also a component of the combined oral contraceptive Natazia, where it is paired with the progestin dienogest in a four-phasic regimen for pregnancy prevention and the management of heavy menstrual bleeding.

From a pharmacokinetic perspective, estradiol valerate exhibits distinct absorption and disposition characteristics following oral administration. The drug is efficiently absorbed from the gastrointestinal tract, and due to its enhanced lipophilicity, it bypasses extensive first-pass degradation to a degree that allows therapeutic serum concentrations of estradiol to be achieved. After absorption, it undergoes rapid hydrolysis by esterases present in the intestinal mucosa, liver, and blood, releasing estradiol and valeric acid. The liberated estradiol then follows the natural metabolic pathways of endogenous estrogen, undergoing interconversion to estrone and estriol, and conjugation primarily to sulfate and glucuronide metabolites for renal excretion. Maximum plasma concentrations of estradiol are typically reached within several hours of dosing, and the pharmacokinetic profile is influenced by food intake, with fed conditions potentially altering absorption rates. The terminal half-life of estradiol itself is relatively short, necessitating daily dosing for sustained therapeutic effect. Clinical studies have demonstrated bioequivalence between various generic formulations and the innovator product, confirming that predictable and consistent hormone levels can be achieved with this therapy.

The safety and adverse effect profile of estradiol valerate is well characterized and reflects its potent estrogenic activity throughout the body. Common side effects associated with its use include breast tenderness or enlargement, nausea, headache, bloating, mood changes including depression or irritability, and intermenstrual bleeding or changes in menstrual flow. These effects are often dose-dependent and may diminish with continued use or dose adjustment. More serious potential risks, particularly with long-term use, include an increased risk of venous thromboembolism, stroke, myocardial infarction, and certain hormone-sensitive cancers, most notably endometrial cancer when estrogens are used without opposing progestin in women with an intact uterus. This necessitates careful patient selection, regular medical follow-up, and the inclusion of a progestin for endometrial protection when indicated. Estradiol valerate is contraindicated in pregnancy, in women with undiagnosed abnormal genital bleeding, a history of breast cancer or other estrogen-dependent tumors, active or prior arterial thromboembolic disease, and liver dysfunction or disease. Regarding lactation, while estradiol appears in breast milk in small amounts, estradiol valerate has historically been used to suppress lactation, and current expert opinion recommends avoiding its use in breastfeeding mothers, particularly before milk supply is well established, due to potential negative effects on milk production.